NEW ZEALAND GAZETTE, No. 53 — 14 MAY 2015

3.8 3-methoxytyramine (including free 3-methoxytyramine and 3-methoxytyramine liberated from its conjugates) at a mass concentration of 4.0 milligrams per litre of urine;

3.9 salicylic acid at a mass concentration of 750 milligrams per litre in urine, or 6.5 milligrams per litre in plasma;

3.10 testosterone (including both free testosterone and testosterone liberated from its conjugates):

3.10.1 at a mass concentration of 20.0 micrograms per litre in urine in geldings;

3.10.2 at a mass concentration of 55.0 micrograms per litre in urine in fillies and mares;

3.10.3 in fillies and mares that have been notified as pregnant at any concentration.

3.11 theobromine at a mass concentration of 2.0 milligrams per litre in urine.

4 The following therapeutic substances are excluded from paragraphs 1.1 to 1.3 when present at or below the following limits (including both the free substance and that substance liberated from any conjugates):

4.1 Diclofenac at a mass concentration of 50.0 micrograms per litre in urine.

4.2 Flunixin at a mass concentration of 100.0 micrograms per litre in urine.

4.3 Ketoprofen at a mass concentration of 100.0 micrograms per litre in urine.

4.4 Meloxicam at a mass concentration of 10.0 micrograms per litre in urine.

4.5 Naproxen at a mass concentration of 250.0 micrograms per litre in urine.

4.6 Phenylbutazone at a mass concentration of 100.0 micrograms per litre in urine.

4.7 Carprofen at a mass concentration of 100.0 micrograms per litre in urine.

4.8 Furosemide at a mass concentration of 50.0 micrograms per litre in urine.

Part B:

5 The following substances are declared as Prohibited Substances for the purposes of these Rules for any day, including a day on which a horse is racing in a Race or trial to which the Third Appendix applies or a day on which a horse is not racing:

5.1 any substance for which there is no generally accepted equine veterinary therapeutic purpose;

5.2 any substance defined as a controlled drug by the Misuse of Drugs Act 1975;

5.3 agents modifying myostatin function, including but not limited to myostatin inhibitors;

5.4 AMPK activators, including but not limited to AICAR (5-amino-1-β-D-ribofuranosyl-imidazole-4-carboxamide);

5.5 aromatase inhibitors;

5.6 beta-2 agonists, unless the substance is prescribed by a veterinarian as a bronchodilator and administered at the dose rate and frequency prescribed;

5.7 cannabinoids;

5.8 endorphins;

5.9 erythropoiesis-stimulating agents, including but not limited to erythropoietin (EPO), epoetin alfa, epoetin beta, darbepoetin alfa, and methoxy polyethylene glycol-epoetin beta (Mircera);

5.10 growth hormones and growth hormone releasing factors;

5.11 hypoxia inducible factor (HIF)-1 stabilisers, including but not limited to ITPP (myo-inositol trispyrophosphate);

5.12 insulin-like growth factor-1 (IGF-1) and other growth factors;

5.13 insulins;

5.14 agents that directly or indirectly affect or manipulate gene expression;

5.15 oxygen carriers including but not limited to perfluorochemicals, efaproxiral, and modified haemoglobin products;

5.16 peroxisome proliferator activated receptor δ (PPARδ) agonists, including but not limited to GW 1516;

5.17 selective androgen receptor modulators (SARMS);

5.18 selective estrogen receptor modulators (SERMS) and other anti-estrogenic substances;

5.19 selective opiate receptor modulators (SORMS);

245